Turmeric and LED in the treatment of sore throat

INTERVENTION: All patients with clinical suspicion of pharyngotonsillitis will be examined and investigated for fever, tonsillar hypertrophy, tonsillar exudates, anterior cervical adenomegaly, mucosal lesions (petechiae, vesicles, exulcerations), cough, nasal obstruction, tearing and diarrhea. Patients will then be assessed for inclusion and exclusion criteria. Once admitted to the study, oropharynx smears will be collected for rapid testing for EBHGA, Gram staining and general culture on blood, chocolate and MacConkey; polymerase chain reaction for Fusobacterium necrophorum (Bank F et al., 2010) and panel detection of respiratory viruses by polymerase chain reaction (influenza A and B viruses, adenovirus, Rhinovirus, coronavirus and EBV). According to the positivity in the rapid test for EBGA detection, the patient will be divided into groups A (TR +) and Group B (TR‐). As patients are admitted to groups A and B, they will be randomly divided again to receive photodynamic therapy (PDT) or not. In this way four groups of participants will be constituted: Group A1 = Antibiotic therapy + photodynamic therapy Group A2 = Antibiotic therapy + placebo of photodynamic therapy Group B1 = Photodynamic therapy Group B2 = Placebo of photodynamic therapy A total of 1.2 x (22 + 82) = 125 patients should be included. Thus, the distribution of a total of 126 patients will be: Group A1: 13 patients Group A2: 13 patients Group B1: 50 patients Group B2: 50 patients Patients selected for photodynamic therapy will suck two bullets with photosensitizer (FS), the natural curcumin from PDT Pharma (http://www.pdtpharma.com.br/). Th CONDITION: Pharyngotonsillitis; bacterial infections and mycoses; pharyngitis; pathological conditions, signs and symptoms; acute tonsillitis ; Respiratory ; Other acute upper respiratory infections of multiple sites PRIMARY OUTCOME: Negativation of counting colonies of EBHGA in culture of oropharyngeal swabs, verified after five minutes and after two days of intervention SECONDARY OUTCOME: Fever resolution, verified by the rate of fever resolution in two days of treatment, and by the number of days until fever resolution INCLUSION CRITERIA: 1. Age between 18 and 45 2. Signature of the Informed Consent Form 3. Presence of fever > 38ºC, oropharyngeal hyperemia, hypertrophy or presence of exudate in palatine tonsils